NCT04974749View on ClinicalTrials.gov

A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

January 3, 2024

Study Completion Date

January 3, 2024

Conditions
Fabry Disease
Interventions
BIOLOGICAL

REPLAGAL

REPLAGAL IV infusion.

Trial Locations (6)

Dongcheng District

Peking Union Medical College Hospital, Beijing

Kaifu District

Xiangya Hospital, Central South University, Changsha

Wuhou District

West China Hospital, Sichuan University, Chengdu

Xiacheng District

The Children's Hospital of Zhejiang University School of Medicine, Hangzhou

Huaiyin District

Shandong Provincial Hospital, Jinan

Huangpu District

Ruijin Hospital, Shanghai Jiaotong Uni. School of Med., Shanghai

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04974749 - A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease | Biotech Hunter | Biotech Hunter